Richard Levy, PhD, Sr. VP of Scientific and Regulatory Affairs Stepping Down After 13 Years

PDA is pleased to welcome Tina Morris, PhD, as the Association’s new Vice President of Scientific and Regulatory Affairs. Currently, she serves as Senior Vice President of Compendial Sciences at the U.S. Pharmacopeia, with whom she has worked for 15 years. She will join the PDA family effective June 4.

Tina Morris

In her new role, Morris will oversee PDA’s scientific and regulatory affairs activities, which include industry-leading technical reports, the newly launched standards-development program through the American National Standards Institute (ANSI), regulatory commenting, and overseeing PDA’s four technical/regulatory advisory boards.

“Dr. Morris has strong leadership capabilities in a volunteer-based organization that we believe are essential to PDA’s efforts to continue PDA’s legacy of leadership in bio/pharmaceutical science,” said Richard Johnson, President and CEO, PDA.

Morris began her career at USP as a Senior Scientific Liaison in 2003, and saw her responsibilities grow each year before becoming Senior Vice President in 2015. Prior to USP, she worked for Human Genome Sciences, Inc. and at Ciphergen Biosystems, Inc. She received her PhD in molecular virology from the Medical University of Luebeck, Germany and a Bachelor of Science and Master of Science in biology from the Carl von Ossietzky University in Oldenburg, Germany.

Richard Levy, PhD, PDA’s outgoing Senior Vice President of Scientific and Regulatory Affairs, announced his retirement earlier this year after 13 years in the role. Among his many accomplishments in the role, Levy oversaw a marked increase in the number of technical documents published annually, the conversion of the PDA Journal of Pharmaceutical Science and Technology from a print to an online-only publication, and the growth in the number of staff in the Scientific and Regulatory Affairs department to better support the efforts of member volunteers. He will take on the role of Editor of the PDA Journal of Pharmaceutical Science andTechnology on May 21.

Richard Levy

“Dr. Levy’s many contributions to PDA, both as a volunteer for many years and as part of the staff since 2005, are numerous,” said Johnson. “He was most instrumental in ramping our technical activities to a level higher than any time in our history. We look forward to working with Dr. Levy as the editor of the Journal for many years to come.”